SCHEMBL4258337

SCHEMBL4258337

Cc1ccc(C=O)c(C=Cc2ccc3c(c2)NC(=O)CO3)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 2/20 0.61
MMP12 P39900 1/20 0.61
PARP1 P09874 2/20 0.45
DRD2 P14416 3/20 0.44
DRD4 P21917 3/20 0.44
DRD3 P35462 2/20 0.44
ALDH1A1 P00352 4/20 0.43
MAPT P10636 4/20 0.43
KDM4E B2RXH2 2/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
LMNA P02545 1/20 0.42
PKM P14618 2/20 0.42
TRPV1 Q8NER1 1/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13932112 1.00 NR3C2 (0.61) NR3C2MMP12PARP1DRD2DRD4
SCHEMBL4269356 0.88 MMP12 (0.64) NR3C2MMP12PARP1DRD2DRD4
SCHEMBL13932049 0.88 MMP12 (0.64) NR3C2MMP12PARP1DRD2DRD4
SCHEMBL27731422 0.87 NR3C2 (0.65) NR3C2MMP12PARP1DRD2DRD4
SCHEMBL13932100 0.86 NR3C2 (0.68) NR3C2MMP12PARP1DRD2DRD4
SCHEMBL4267625 0.86 NR3C2 (0.68) NR3C2MMP12PARP1DRD2DRD4
SCHEMBL4272473 0.82 MMP12 (0.65) NR3C2MMP12PARP1ALDH1A1MAPT
SCHEMBL13932083 0.82 MMP12 (0.65) NR3C2MMP12PARP1ALDH1A1MAPT
SCHEMBL13932042 0.81 NR3C2 (0.63) NR3C2MMP12PARP1ALDH1A1KDM4E
SCHEMBL4266691 0.81 NR3C2 (0.63) NR3C2MMP12PARP1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 NR3C2 7/4885MMP12 2999/4885PARP1 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.